Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A2 | P11168 | 15/20 | 0.71 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.45 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17719031 | 0.90 | SLC2A2 (0.76) | SLC2A2SLC2A1 | |
| SCHEMBL17719082 | 0.88 | SLC2A2 (0.72) | SLC2A2SLC2A1KCNK3KCNK9 | |
| SCHEMBL17719072 | 0.86 | SLC2A2 (0.70) | SLC2A2SLC2A1EPHX2 | |
| SCHEMBL17719058 | 0.85 | SLC2A2 (0.68) | SLC2A2SLC2A1KCNK3KCNK9 | |
| SCHEMBL17719035 | 0.84 | SLC2A2 (0.67) | SLC2A2SLC2A1KCNK3KCNK9 | |
| SCHEMBL17719064 | 0.84 | SLC2A2 (0.67) | SLC2A2SLC2A1KCNK3KCNK9 | |
| SCHEMBL17719056 | 0.84 | SLC2A2 (0.67) | SLC2A2SLC2A1KCNK3KCNK9 | |
| SCHEMBL17719090 | 0.83 | SLC2A2 (1.00) | SLC2A2SLC2A1KCNK3KCNK9 | |
| SCHEMBL17719120 | 0.78 | SLC2A2 (1.00) | SLC2A2SLC2A1 | |
| SCHEMBL17719137 | 0.78 | SLC2A2 (1.00) | SLC2A2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | IOMET PHARMA LTD. (GB) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120863-A1 | SLC2A TRANSPORTER INHIBITORS | SLCO1A2, SLCO2B1, SLCO2A1 | SLC2A2 8/4885SLC2A1 6/4885EPHX2 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.